factual

AveXis Pre-IPO Investment Outcome

RTW invested in AveXis at the pre-IPO round when it was about a $500 million company; it IPO'd in early 2016, a terrible year for biotech, and fell under pressure when venture investors sold six months later, but with only preclinical animal data RTW kept adding, and the company was sold to Novartis for almost $9 billion within about two years after an approved therapy.

factualpending

Speaker

Stephanie

Evidence Quote

“We got in at the pre-IPO round... they IPO-ed in early 2016, which was a terrible year for biotech... within two years, it was sold to Novartis for almost $9 billion”

Source

RTW: Investing Across Healthcare— Business Breakdowns
Created: 11/13/2026, 1:54:32 PM

Your notes

Loading notes...